| Dr Nael Kilzieh, MD | |
|
Vapshcs, American Lake Div. 116-m, Tacoma, WA 98493 | |
| (253) 583-1703 | |
| (253) 589-4167 |
| Full Name | Dr Nael Kilzieh |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | Vapshcs, American Lake Div. 116-m, Tacoma, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033226568 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00029398 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nael Kilzieh, MD Vapshcs, American Lake Div. 116-m, Tacoma, WA 98493 Ph: (253) 583-1703 | Dr Nael Kilzieh, MD Vapshcs, American Lake Div. 116-m, Tacoma, WA 98493 Ph: (253) 583-1703 |
News Archive
The Wall Street Journal reports the plan would scale back money for public health and prevention programs; The Associated Press covers the debate about the proposed defense budget, which would scale back retirees' health coverage.
Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss, according to new research at Wake Forest University Baptist Medical Center.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
› Verified 8 days ago
Daniel Magliozzi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Va American Lake 9600 Veterans Drive Southwest, Tacoma, WA 98493 Phone: 215-589-3937 | |
Dr. Rolando C Pasion, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 9601 Steilacoom Blvd Sw, Tacoma, WA 98498 Phone: 253-582-8900 Fax: 253-756-2879 | |
Dr. Robert Edward Sands, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3609 So 19th St, Robert E Sands Md, Tacoma, WA 98405 Phone: 253-752-6056 Fax: 253-759-7129 | |
Cristina Cruz-crespo, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Madigan Army Medical Center-neurology, 9040a Fitzsimmons Drive, Tacoma, WA 98431 Phone: 787-968-1754 | |
Stephanie Lois Leong, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-3885 | |
Sandeep Saran, D.O Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Madigan Army Medical Center 9040 Jackson Avenue, Tacoma, WA 98431 Phone: 253-968-2252 |